Pre-diagnostic dynamic HPV16 IgG seropositivity and risk of oropharyngeal cancer: Methodologic issues
We thank Erfan Ayubi and Saeid Safiri for their comments on our manuscript, Pre-diagnostic dynamic HPV16 IgG seropositivity and risk of oropharyngeal cancer, published in Oral Oncology in October 2017. In particular, we appreciate their identification of a transcription error in the upper bound of the confidence interval for the adjusted odds ratio of seropositivity with years prior to diagnosis in the 0 –2 years category. The reported result of OR = 85.2, CI = 13.7–68.5 should have been OR = 85.2, CI = 13.7–684.6. (Source: Oral Oncology)
Source: Oral Oncology - March 29, 2018 Category: Cancer & Oncology Authors: Karen S. Anderson, Jon Mork, Hilde Langseth, Garrick Wallstrom Tags: Letter to the editor Source Type: research
Responses in patients receiving sequential paclitaxel post progression on PD1 inhibitors
This report describes highlights the dramatic responses seen in patients who were given paclitaxel post progression on immunotherapy. There are multiple mechanisms by which synergistic effects of immunotherapy and chemotherapy occur. Further prospective studies on chemotherapy and immunotherapy are eagerly awaited. (Source: Oral Oncology)
Source: Oral Oncology - March 28, 2018 Category: Cancer & Oncology Authors: Ammar Sukari, Misako Nagasaka, Nadine Abdallah Tags: Letter to the editor Source Type: research
Editorial Board/Aims & Scope
(Source: Oral Oncology)
Source: Oral Oncology - March 27, 2018 Category: Cancer & Oncology Source Type: research
Locally advanced squamous cell carcinoma of the head and neck: A systematic review and Bayesian network meta-analysis of the currently available treatment options
CCRT with cisplatin remains the gold standard of treatment. Taxane based IC regimens may have a impact on locally advanced disease. Altered fractionation RT is inferior to CCRT and also does not seem to be meaningfully better than conventionally fractionated RT alone. Its role in locally advanced disease should be reevaluated. (Source: Oral Oncology)
Source: Oral Oncology - March 27, 2018 Category: Cancer & Oncology Authors: Oreste Iocca, Alessio Farcomeni, Arianna Di Rocco, Pasquale Di Maio, Pawe ł Golusinski, Simón Pardiñas López, Alfredo Savo, Raul Pellini, Giuseppe Spriano Source Type: research
Data-Driven prioritisation of antibody-drug conjugate targets in head and neck squamous cell carcinoma
Head and neck squamous cell carcinoma (HNSCC) is the seventh most common type of cancer worldwide accounting for 600.000 new cases and 250.0000 cancer deaths each year [1,2]. At initial diagnoses, ∼40% of patients have early stage disease, ∼50% locally advanced disease and 10% metastatic disease [3]. Despite multimodality treatment with curative intent, at least 50% of initially treated patients develop recurrent or metastatic disease within two years [3]. Patients with metastatic or recu rrent disease that is not amenable to therapy with curative intent have a median overall survival of less than 12 months [4]. (Source: Oral Oncology)
Source: Oral Oncology - March 27, 2018 Category: Cancer & Oncology Authors: Saskia H. Hanemaaijer, Stephanie E. van Gijn, Sjoukje F. Oosting, Boudewijn E.C. Plaat, Kirsten L. Moek, Ed M. Schuuring, Bernard F.A.M. van der Laan, Jan L.N. Roodenburg, Marcel A.T.M. van Vugt, Bert van der Vegt, Rudolf S.N. Fehrmann Source Type: research
Letter to the Editor referring to the retracted publication entitled “Straticyte demonstrates prognostic value over oral epithelial dysplasia grade for oral potentially malignant lesion assessment” by Hwang et al.
After our article entitled “Straticyte demonstrates prognostic value over oral epithelial dysplasia grade for oral potentially malignant lesion assessment” [1] was published in Oral Oncology, we responded to a reader’s query and provided our data at the Editor-in-Chief’s request. In reviewing the data, we discovered t hat a calculation error had occurred which changed the sensitivity from 71% to 48% and negative predictive value from 60% to 36% for the Straticyte assay in the high-risk vs. non-high-risk subgroups. (Source: Oral Oncology)
Source: Oral Oncology - March 24, 2018 Category: Cancer & Oncology Authors: Jason T.K. Hwang, Ying R. Gu, Benjamin J. Dickson, Mi Shen, Ranju Ralhan, Paul G. Walfish, David Mock, Kenneth P.H. Pritzker Tags: Letter to the editor Source Type: research
Hypoxia induced EMT: A review on the mechanism of tumor progression and metastasis in OSCC
Head and neck cancer encompasses the cancer of the oral cavity, paranasal sinuses, pharynx, and larynx [1,2]. Head and Neck cancer, which develops at the lips, tongue, salivary glands, gingiva, floor of the mouth, oropharynx, buccal surfaces and other intra-oral locations [3], is the sixth most common cancer in the world [4]. The GLOBOCAN 2012 report indicated an estimated 300,400 new cases and 145,400 deaths due to oral cancer, with the highest rates being found in Melanesia and South-Central and Eastern Asia [5,6]. (Source: Oral Oncology)
Source: Oral Oncology - March 20, 2018 Category: Cancer & Oncology Authors: Joel P. Joseph, M.K. Harishankar, Aruthra Arumugam Pillai, Arikketh Devi Tags: Review Source Type: research
Low grade parotid mucoepidermoid carcinoma with tumour associated lymphoid proliferation ( “Warthin-like”) and CRTC1-MAML2 fusion transcript: Definitive diagnosis with molecular investigation only
We report a particular type of mucoepidermoid carcinoma (MEC) of the parotid gland, with intense “tumour associated lymphoid proliferation” (TALP) which presented CRTC1-MAML2 fusion transcript. (Source: Oral Oncology)
Source: Oral Oncology - March 20, 2018 Category: Cancer & Oncology Authors: Iolia Akaev, Chit Cheng Yeoh, Peter A. Brennan, Siavash Rahimi Tags: Letter to the editor Source Type: research
Definitive chemoradiation for locally-advanced oral cavity cancer: A 20-year experience
An estimated 32,670 new cases of oral cavity carcinoma will be diagnosed in the United States in 2017, and an estimated 6650 patients will die from this disease [1]. Thus, oral cancer remains a significant cause of morbidity and mortality despite decreasing rates of tobacco use, and oral cavity squamous cell carcinoma (OC-SCC) is the most common histologic diagnosis. While tobacco abuse is the strongest risk factor for the development of OC-SCC, concomitant alcohol consumption may synergistically increase risk [2]. (Source: Oral Oncology)
Source: Oral Oncology - March 16, 2018 Category: Cancer & Oncology Authors: Corey C. Foster, James M. Melotek, Ryan J. Brisson, Tanguy Y. Seiwert, Ezra E.W. Cohen, Kerstin M. Stenson, Elizabeth A. Blair, Louis Portugal, Zhen Gooi, Nishant Agrawal, Everett E. Vokes, Daniel J. Haraf Source Type: research
Assessing the potential role of scaffold-mediated local chemotherapy in oral cancer
Chemotherapy entails a fine balance between inducing cytotoxicity in cancer cells while preserving the integrity of the normal cells. Chemotherapy, unlike surgery or radiotherapy, is not precisely targeted and leads to non-selective accumulation of drugs in healthy tissues. The past decade has seen the invent of several targeted therapy systems to minimize cytotoxic effects on healthy tissues [1 –3]. The nanoparticle-mediated delivery system has gained popularity in the past two decades. Although nanoparticles aid in the targeted delivery of the chemotherapeutic agents, the nanoparticles (Doxil, gold, silver, etc.) thems...
Source: Oral Oncology - March 16, 2018 Category: Cancer & Oncology Authors: Archana A. Gupta, Nikhil Pande, Supriya Kheur, A. Thirumal Raj Tags: Letter to the editor Source Type: research
